Aileron Therapeutics, Inc. (ALRN) 2021年年度报告「NASDAQ」.pdf

《Aileron Therapeutics, Inc. (ALRN) 2021年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Aileron Therapeutics, Inc. (ALRN) 2021年年度报告「NASDAQ」.pdf（148页珍藏版）》请在三个皮匠报告上搜索。

1、Annual Report 2021TRANSFORMING THE EXPERIENCE OF CHEMOTHERAPY FOR PATIENTSKEYEPO=Erythropoietin;G-CSF=Granulocyte Colony-Stimulating Factor;NSCLC=Non-Small Cell Lung CancerSincerely,MANUEL AIVADO,M.D.,PH.D.PRESIDENT&CEODear Stockholders,At Aileron,we aim to introduce a new era in supportive care by

2、delivering the first precision medicine drug to prevent chemotherapy-induced side effects for cancer patients.Preventing side effects can save lives,can enable patients to have a better quality of life,and can help patients fight cancer more effectively.In 2021,we made tremendous progress toward ach

3、ieving our goal,and we look forward to another productive year in 2022,including three anticipated clinical data readouts.OUR POTENTIAL TO REVOLUTIONIZE SUPPORTIVE CAREDeliver the first precision medicine-based supportive care drug.To date,there are no precision medicine-based supportive care drugs.

4、Aileron is pioneering a precision medicine approach known as selective chemoprotection to exclusively treat patients with p53-mutated cancers who are receiving chemotherapy.ALRN-6924 is designed to selectively protect these patients healthy cells from chemotherapy without interfering with chemothera

5、pys effects on cancer cells.Nearly 1 million patients are diagnosed each year with p53-mutated cancerin the US.Deliver a single medicine that can prevent multiple toxicities.Most existing supportive care drugs are designed to treat a single chemotherapy-induced toxicity,such as neutropenia(G-CSF)or

6、anemia(EPO),and most often they are administered after chemotherapy has damaged healthy cells.ALRN-6924,which is designed to prevent multiple chemotherapy induced toxicities including neutropenia,thrombocytopenia and anemia is administered before chemotherapy,with the goal of preventing chemotherapy